Three new candidate drugs are being tested in the latest phase of global Solidarity clinical trials to find effective treatments against COVID-19, the World Health Organisation announced on Wednesday.

The therapies — artesunate, imatinib and infliximab — will be tested on hospitalised COVID-19 patients in 52 countries under the Solidarity PLUS programme.

There have been more than 203 million cases of the disease recorded globally as of Wednesday, according to WHO.

The world hit the 200 million mark last week, just six months after cases passed 100 million.

Speaking during a press conference in Geneva, WHO’s Director-General, Dr Tedros Ghebreyesus underscored the critical need to find more effective and accessible COVID-19 therapeutics.

“We already have many tools to prevent, test for and treat COVID-19, including oxygen, dexamethasone and IL-6 blockers.

“But we need more, for patients at all ends of the clinical spectrum, from mild to severe disease. And we need health workers that are trained to use them in a safe environment,” he said.

The three drugs were selected by an independent panel for their potential in reducing the risk of death in people hospitalised for COVID-19.

They are already being used to treat other conditions.

Artesunate is a medicine for severe malaria, imatinib is used for certain cancers, including leukemia, while infliximab is used to treat Crohn’s Disease, rheumatoid arthritis and other diseases of the immune system.

Manufacturers Ipca, Novartis and Johnson & Johnson, donated the drugs for the trial.

Solidarity PLUS is the largest global collaboration among WHO’s 194 Member States, with thousands of researchers in over 600 hospitals participating.

Finland is among the 52 countries taking part, 16 more than the initial Solidarity Trial, and contributes to the COVAX vaccine solidarity initiative. Two university hospitals in Finland have been the first worldwide to begin the second phase.

Hanna Sarkkinen, the country’s Minister of Social Affairs and Health, said clinical trials had a great potential to save lives.

“Even though there are approximately 3,000 clinical studies on COVID-19, most of them are too small to yield significant information. We need clinical trials that are large enough to bring better treatments for COVID-19 patients,” she said.

Four drugs were evaluated under the initial Solidarity Trial in 2020, which showed that remdesivir, hydroxychloroquine, lopinavir, and interferon had little or no effect on hospitalised patients with COVID-19.

______________________________________________________________________ “Enhance Legal Practice With Authoritative Reports” — Alexander Payne Offers Comprehensive Law Reports, Spanning Over A Century Of Nigerian Jurisprudence

Interested buyers are encouraged to place their orders and enquiries via: 0704 444 4777, 0704 444 4999, 0818 199 9888 Website: www.alexandernigeria.com

_______________________________________________________________________ [A MUST HAVE] Evidence Act Demystified With Recent And Contemporary Cases And Materials
“Evidence Act: Complete Annotation” by renowned legal experts Sanni & Etti.
Available now for NGN 40,000 at ASC Publications, 10, Boyle Street, Onikan, Lagos. Beside High Court, TBS. Email publications@ayindesanni.com or WhatsApp +2347056667384. Purchase Link: https://paystack.com/buy/evidence-act-complete-annotation _______________________________________________________________________

“Order Justice Omolaye-Ajileye’s Electronic Evidence Books Now” — Essential Guides On Evidence Act, Case Law And Digital Proof

Two leading books on electronic evidence by Hon. Justice Professor Alaba Omolaye-Ajileye, Rtd., PhD, FICMC, are now available for purchase. The publications, Electronic Evidence (Second Edition), With The Evidence Act, 2011 and Compendium Of Cases On Electronic Evidence, Volume II, 2020–2025, provide practical guidance, legal analysis and recent judicial authorities on electronic evidence in Nigeria.Order directly from the author here: https://velvety-cendol-7387ed.netlify.app/ _______________________________________________________________________ Groundbreaking Guide For Lawyers: Adigwe Publishes ‘Artificial Intelligence For Lawyers’ With Free Research eBook The book also examines Nigeria's legal ecosystem, focusing on the LPELR and NBA AI Guidelines. As a bonus, every purchase comes with a FREE eBook titled: How to Use the AI Features in LegalPedia and LawPavilion. Ohio Books Ltd praises the publication, stating: "....this is the only Nigerian book I know of on the topic." How to Order: 📞 Call, Text, or WhatsApp: 08034917063 | 07055285878 📧 Email: benadigwe1@gmail.com 🌎 Website: www.benadigwe.com Ebook Version: Access it directly online at https://selar.com/prv626 Authored by Ben Ijeoma Adigwe Esq., ACIarb (UK), LL.M, Dip. in Artificial Intelligence, Director at the Delta State Ministry of Justice, Asaba, Nigeria. _______________________________________________________________________